| Angioedemas, Hereditary
Kalbitor vs Takhzyro
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Kalbitor vs Takhzyro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTakhzyro has a higher rate of injection site reactions vs Kalbitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Takhzyro but not Kalbitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kalbitor
Takhzyro
At A Glance
SC injection
As needed
Plasma kallikrein inhibitor
SC injection
Every 2-4 weeks
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Angioedemas, Hereditary (adults and pediatric >=12 years) 300 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 6 to <12 years) 150 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 2 to <6 years) 150 mg SC every 4 weeks.
Contraindications
- Known clinical hypersensitivity to KALBITOR
—
Adverse Reactions
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Most common (>=10%) Injection site reactions, upper respiratory infections, headache, rash, dizziness, diarrhea, myalgia.
Less common Hypersensitivity, increased aspartate transaminase, increased alanine transaminase.
Pharmacology
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Plasma kallikrein inhibitor; lanadelumab-flyo is a fully human IgG1/kappa monoclonal antibody that binds and inhibits plasma kallikrein, reducing cleavage of high-molecular-weight kininogen and excess bradykinin generation that causes increased vascular permeability and angioedema attacks in HAE patients with C1-inhibitor deficiency or dysfunction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Takhzyro
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Takhzyro
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Takhzyro
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KalbitorView full Kalbitor profile
TakhzyroView full Takhzyro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.